RE: Que?30 Oct 2022 08:15
From Bermudashorts on the other board:-
Trucheck is a liquid biopsy being offered by Datar Cancer Genetics, an Indian company with labs in Germany and the UK, coincidentally also at the Surrey Research Park in Guildford as gooosed has pointed out.
They are offering the TruCheck test based on results from some massive clinical trials in India, but it's a very different beast to Parsortix. Essentially, they take 15ml of blood and treat it with they call 'epigenetically activated media' - essentially a ****tail of various enzymes, transcription factors etc. The blood is treated over a period of at least 5 days and the idea is that normal cells are killed and only tumour associated cells remain, these can be CTCs, but also other tumour associated cells such as macrophages and fibroblasts.
After 5 days, the remaining living cells are identified using antibody based multiplexed fluorescence immunocytochemistry (ICC). So whilst the methodology might be different, it does seem to be another antibody based system - ie. the cells are ony picked up and identified if they express certain markers.
The biggest difference though comes in the setting for the TruCheck test which is as a screening tool for early diagnosis. It is in the same space as Grail and other ctDNA liquid biospies. It's purely an assay to simply establish the presence of certain cells whereas Parsortix captures the live cells which can then be used for downstream analysis.
For those who maybe haven't appreciated the potential of the ovarian assay, it's worth noting this is a good example of the commercial potential of an accredited lab offering their own LDT.
Sign In
Follow the stocks
